On September 24th, Grorange reported that eli lilly and co announced on Tuesday that its Alzheimer's drug donanemab has been approved by the Japanese Ministry of Health, Labor and Welfare, providing a new treatment option for Japanese patients after the approval of Weiju and Bais. Japan is the second major market where donanemab has been approved, and the drug was previously marketed in the usa under the brand name Kisunla.
礼来的阿尔茨海默病药物donanemab在日本获批
Eli Lilly and Co's Alzheimer's drug donanemab has been approved in Japan
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.